Advanced T cell therapy : current research

This research team belongs to the UMR 1015 - Tumor immunology and immunotherapies

We develop genome editing approaches derived from CRISPR-cas9 technology (inactivation, activation, base editing, genome-wide) to understand the biology of T cells but also improve the composition, functionality, and persistence of therapeutic cell products, CAR-T, and TILs (tumor-infiltrating lymphocytes).